Investors Oct 24, 2019Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer Aug 05, 2019News from LipoMedix: LipoMedix Appoints New Members to Board of Directors and Creates New Executive Committee Apr 13, 2018Press Release from Rafael Pharmaceuticals: Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia 1 2 3 4 << < > >>
